IRIS - Res&Arch Institutional Research Information System - Research & Archive

RIUZZI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.162
AS - Asia 3.479
EU - Europa 3.098
SA - Sud America 671
Continente sconosciuto - Info sul continente non disponibili 264
AF - Africa 74
OC - Oceania 6
Totale 12.754
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.021
SG - Singapore 1.521
IT - Italia 676
BR - Brasile 537
HK - Hong Kong 527
CN - Cina 477
UA - Ucraina 472
IE - Irlanda 443
RU - Federazione Russa 353
VN - Vietnam 272
KR - Corea 197
DE - Germania 196
SE - Svezia 179
FR - Francia 159
FI - Finlandia 137
GB - Regno Unito 131
IN - India 86
BD - Bangladesh 73
CA - Canada 72
NL - Olanda 70
RO - Romania 56
TR - Turchia 53
AR - Argentina 44
AT - Austria 44
IQ - Iraq 43
JP - Giappone 33
PL - Polonia 32
ES - Italia 30
CO - Colombia 29
PH - Filippine 28
PK - Pakistan 24
CH - Svizzera 23
MX - Messico 23
EC - Ecuador 21
BE - Belgio 20
ZA - Sudafrica 20
ID - Indonesia 19
CZ - Repubblica Ceca 18
UZ - Uzbekistan 16
MY - Malesia 15
SA - Arabia Saudita 14
VE - Venezuela 14
CL - Cile 11
JM - Giamaica 11
LB - Libano 11
EG - Egitto 10
MA - Marocco 10
TN - Tunisia 9
CR - Costa Rica 8
AE - Emirati Arabi Uniti 7
EE - Estonia 7
IR - Iran 7
LT - Lituania 7
MD - Moldavia 7
PY - Paraguay 7
GR - Grecia 6
PE - Perù 6
TW - Taiwan 6
AZ - Azerbaigian 5
BG - Bulgaria 5
ET - Etiopia 5
IL - Israele 5
JO - Giordania 5
KH - Cambogia 5
NI - Nicaragua 5
TH - Thailandia 5
BA - Bosnia-Erzegovina 4
DO - Repubblica Dominicana 4
KG - Kirghizistan 4
OM - Oman 4
AU - Australia 3
EU - Europa 3
GT - Guatemala 3
HU - Ungheria 3
KE - Kenya 3
NZ - Nuova Zelanda 3
PA - Panama 3
RS - Serbia 3
TT - Trinidad e Tobago 3
BY - Bielorussia 2
DK - Danimarca 2
GE - Georgia 2
HN - Honduras 2
HR - Croazia 2
KW - Kuwait 2
KZ - Kazakistan 2
LV - Lettonia 2
MU - Mauritius 2
NG - Nigeria 2
NO - Norvegia 2
NP - Nepal 2
PR - Porto Rico 2
PS - Palestinian Territory 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
AL - Albania 1
BB - Barbados 1
Totale 12.470
Salva come PNG Salva come JPEG
Città #
Singapore 1.190
Chandler 544
Hong Kong 513
Dublin 438
San Jose 413
Ashburn 398
Jacksonville 257
San Mateo 228
Santa Clara 192
Boardman 178
Perugia 170
Council Bluffs 164
Moscow 130
Seoul 127
Lauterbourg 108
Medford 108
Wilmington 107
Princeton 106
Beijing 104
The Dalles 103
Dong Ket 94
Ann Arbor 89
Los Angeles 88
New York 78
Altamura 75
Andover 59
Ho Chi Minh City 56
Piscataway 53
Munich 52
Lawrence 49
Bucharest 48
Des Moines 46
São Paulo 46
Hanoi 38
Dallas 33
Falls Church 33
Dearborn 32
Vienna 31
Montreal 29
Norwalk 29
Shanghai 29
Turin 29
Helsinki 28
Orem 28
Phoenix 28
Bologna 26
Tokyo 26
Saint Petersburg 25
Redmond 24
Rio de Janeiro 20
Boston 19
Brussels 19
Turku 19
Warsaw 19
Woodbridge 19
Amsterdam 18
Atlanta 18
Brooklyn 18
Chicago 18
Seongnam-si 18
Rome 17
Frankfurt am Main 16
Houston 16
London 16
Milan 16
Stockholm 16
Chennai 15
Denver 15
Falkenstein 15
San Francisco 15
Baghdad 13
Brasília 13
Izmir 13
Johannesburg 13
Buffalo 12
Da Nang 12
Nuremberg 11
Olomouc 11
Philadelphia 11
Redwood City 11
Tashkent 11
Toronto 11
Charlotte 10
Dhaka 10
Ankara 9
Cebu City 9
Groningen 9
Manchester 9
Mumbai 9
Parma 9
Columbus 8
Haiphong 8
Incheon 8
Istanbul 8
New Delhi 8
Cairo 7
Glasgow 7
Guangzhou 7
Lahore 7
Naples 7
Totale 7.532
Salva come PNG Salva come JPEG
Nome #
Beneficial effects of horsetail (Equisetum arvense) in experimental models of sarcopenia and osteoporosis 292
Pharmacological targeting of the receptor for advanced glycation end-products (RAGE) to counteract cancer cachexia 204
An HMGB1/RAGE/p38 MAPK/Myogenin Axis Modulates Pax7 Expression in Myoblasts by Both Transcriptional and Post-Transcriptional Mechanisms 189
Targeting RAGE prevents muscle wasting and prolongs survival in cancer cachexia 161
RAGE in the pathophysiology of skeletal muscle. 157
Identification of natural products able to counteract the formation of advanced glycation end-products (AGEs) sustaining muscle atrophy 157
Oxidative stress-induced S100B accumulation converts myoblasts into brown adipocytes via an NF-κB/YY1/miR-133 axis and NF-κB/YY1/BMP-7 axis 154
Equisetum arvense standardized extract hinders age-related sarcopenia 151
Cellular and molecular mechanisms of sarcopenia: the S100B perspective 151
Differential expression of S100B protein and RAGE in young and aged human satellite cells. 148
S100B protein regulates myoblast and macrophage functions in skeletal muscle regeneration 147
Identification of Withania somnifera-Silybum marianum-Trigonella foenum-graecum Formulation as a Nutritional Supplement to Contrast Muscle Atrophy and Sarcopenia 147
Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite 145
A braking circuit between pathogen- and danger-sensing signaling pathways restrains lung inflammation: role of S100B protein, RAGE and Toll-like receptors. 144
Toward the identification of receptor for advanced glycation end-products (RAGE) as a muscle biomarker of cancer cachexia. 144
Ablation of RAGE (receptor for advanced glycation end-products) translates into reduced tumorigenic and cachectic potential in LLC-tumor bearing mice 143
Absence of RAGE in an animal experimental model of Duchenne muscular dystrophy results in reduced muscle necrosis and inflammation 143
Sertoli cells protect C2C12 myotubes against atrophy and induce utrophin expression in canine and human dystrophic myotubes. 142
Natural products to counteract muscle atrophy 142
Amphoterin-induced myogenic differentiation of RAGE-transfected rhabdomyosarcoma TE671 cells 140
Screening of 100 plant extracts for the development of a herbal product effective against muscle atrophy 140
Activation of RAGE in myoblasts and rhabdomyosarcoma cells results in downregulation of Pax7 expression 138
RAGE signalling in myoblasts and embryonal rhabdomyosarcoma cells represses Pax7 expression via p38 MAPK-dependent induction of myogenin. 138
Sertoli cell-secreted factors have promyogenic and antifibrotic properties on human DMD myoblasts with different mutations. 137
RAGE and its ligands, S100B and HMGB1, are molecular determinants of cancer-induced muscle wasting. 136
Glyoxalase 1 sustains the metastatic phenotype of prostate cancer cells via EMT control 134
Amphoterin stimulates myogenesis and counteracts the anti-myogenic factors, bFGF and S100B, via RAGE binding 133
Targeting RAGE as a potential therapeutic approach to Duchenne muscular dystrophy 132
S100B protein, a damage-associated molecular pattern protein in the brain and heart, and beyond 131
Aged vs young human satellite cells: altered expression of S100B and RAGE, and defective ability in conditioning the medium contribute to impaired myogenic potential. 130
RAGE expression in rhabdomyosarcoma cells results in reduced proliferation, migration, and invasiveness in vitro and tumor growth in vivo 125
Hypoxia Promotes Danger-mediated Inflammation via Receptor for Advanced Glycation End Products in Cystic Fibrosis 124
Different intrinsic properties of young and aged human satellite cells. 123
Implication of RAGE and Amphoterin in Myogenesis 121
Involvement of a RAGE/p38MAPK/myogenin axis in cancer cachexia. 121
Appropriate levels of extracellular S100B protein in injured muscle are required for correct muscle regeneration. 120
Employment of Microencapsulated Sertoli Cells as a New Tool to Treat Duchenne Muscular Dystrophy 116
Beneficial effects of horsetail (Equisetum arvense) in in vitro models of sarcopenia and osteoporosis 115
RAGE signaling in myoblasts and rhabdomyosarcoma cells causes downregulation of Pax7 expression via p38 MAPK activation and upregulation of myogenin expression 114
Young and Aged Human Muscle Satellite Cells Show Differential Expression of S100B Protein and RAGE. 114
KYMASIN UP Natural Product Inhibits Osteoclastogenesis and Improves Osteoblast Activity by Modulating Src and p38 MAPK 113
Receptor for advanced glycation end-products (RAGE) as a biomarker of muscle wasting in cancer conditions 113
Microencapsulated Sertoli cells sustain myoblast proliferation without affecting the myogenic potential. In vitro data 113
S100B causes apoptosis in a myoblast cell line in a RAGE-independent manner 110
RAGE engagement in myoblasts modulates proliferation, apoptosis, adhesiveness, migration and invasiveness 109
Genetically-determined hyperfunction of the S100B/RAGE axis is a risk factor for aspergillosis in stem cell transplant recipients 109
Levels of S100B protein drive the reparative process in acute muscle injury and muscular dystrophy 109
Equisetum arvense standardized dried extract hinders age-related osteosarcopenia. 108
The danger signal S100B integrates pathogen- and danger-sensing pathways to restrain inflammation 108
S100B protein in tissue development, repair and regeneration 108
Hyperactivated rage in comorbidities as a risk factor for severe covid-19—the role of rage-ras crosstalk 108
Do porcine Sertoli cells represent an opportunity for Duchenne muscular dystrophy? 107
Caveolins and cavins in muscle-derived tumours. 106
Causes of elevated serum levels of S100B protein in athletes 105
Use of Sertoli cells to treat DMD patients is supported by their immunomodulatory rather than immunosuppressive effect 105
Functions of S100 proteins 104
Defective RAGE activity in embryonal rhabdomyosarcoma cells results in high PAX7 levels that sustain migration and invasiveness 104
S100B's double life: Intracellular regulator and extracellular signal. 103
Novel data support the use of microencapsulated Sertoli cells as a potential treatment of DMD patients. 103
Complex regulatory effects of extracellular S100B on myoblast differentiation: S100B activates quiescent myoblats and satellite cells 102
S100B protein differentially regulates myoblast differentiation via direct binding to RAGE and bFGF-mediated activation of FGFR1 in low-density and high-density cultures, respectively 102
Human muscle satellite cells show age-related differential expression of S100B protein and RAGE. 102
S100 proteins in obesity: liaisons dangereuses 102
Effects of deletion of RAGE in muscle regeneration: preliminary observations. 101
Reductive stress in striated muscle cells 101
S100B engages RAGE or bFGF/FGFR1 in myoblasts depending on its own concentration and myoblast density. Implications for muscle regeneration 99
The receptor RAGE: a potential molecular target in cancer cachexia 99
Sertoli cells induce utrophin expression in human DMD myotubes with different mutations and exert promyogenic and antifibrotic effects 97
Opposing regulatory roles of S100B and amphoterin in myogenic differentiation: RAGE-dependence of amphoterin stimulatory effects vs. RAGE-independence of S100B inhibitory effects 96
RAGE expression in rhabdomyosarcoma cells modulates metastasis formation in vivo. 96
Enforced expression of RAGE in rhabdomyosarcoma cells result in reduced proliferation, migration, and invasiveness in vitro, activation of a myogenic program, and reduced tumor growth in vivo. 96
Elucidating the mechanism of S100B-dependent regulation of myoblast differentiation. 93
RAGE-independence of S100B inhibition of myogenic differentiation and myotube formation 93
Functional inactivation of RAGE in myoblasts results in tumor formation 92
The amphoterin (HMGB1)/receptor for advanced glycation end products (RAGE) pair modulates myoblast proliferation, apoptosis, adhesiveness, migration, and invasiveness. Functional inactivation of RAGE in L6 myoblasts results in tumor formation in vivo 91
Molecular mechanism of S100B-dependent inhibition of myoblast differentiation 91
S100B activates quiescent myoblasts and satellite cells 90
Spatiotemporal regulation of Toll-like receptors and RAGE signaling pathways by S100B protein restrains inflammation 90
S100B protein in skeletal muscle regeneration: regulation of myoblast and macrophage functions 90
Mechanism of S100B-dependent inhibition of myoblast differentiation 87
RAGE expression in rhabdomyosarcoma cells results in myogenic differentiation and reduced proliferation, migration, invasiveness, and tumor growth 87
Differential involvement of RAGE and FGFR1 in S100B effects on myoblast differentiation 86
Delayed Muscle Regeneration in RAGE-/- Skeletal Muscles. 86
Potential role of S100B protein in myogenesis and skeletal muscle regeneration 85
S100B protein accelerates the activation of quiescent myoblasts and muscle satellite cells. 85
HMGB1/RAGE modulates Pax7 expression in myoblasts via p38 MAPK-dependent upregulation of myogenin. 85
The many faces of S100B protein: when an extracellular factor inactivates its own receptor and activates another one. 85
Differential engagement of RAGE and FGFR1 in muscle satellite cells by S100B protein: involvement of RAGE in satellite cell activation and of FGFR1 on satellite cell expansion. 85
Phosphocaveolin-1 Enforces Tumor Growth and Chemoresistance in Rhabdomyosarcoma 85
S100B inhibits myoblast differentiation via activation of a Ras-MEK-ERK1/2 signaling pathway 85
S100B-dependent inhibition of myoblast differentiation: molecular mechanism 84
S100B inhibits myogenic differentiation and myotube formation in a RAGE-independent manner 82
S100B protein restrains inflammation via spatiotemporal regulation of pathogen- and danger-sensing signaling pathways. 82
Grafted Sertoli Cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer 80
S100B causes apoptosis in myoblasts and inhibits myogenic differentiation and myotube formation in a RAGE-independent manner 80
Effects of RAGE expression in rhabdomyosarcoma cells 80
RAGE in tissue homeostasis, repair and regeneration. 80
The novel DMD experimental model, mdx/Ager–/– mouse reveals a role of RAGE in inflammatory processes in dystrophic muscles. 80
RAGE modulates myoblast proliferation, apoptosis, migration and invasiveness 79
Role of CD45 signaling pathway in Galactoxylomannan-induced T cell damage. 79
Totale 11.458
Salva come PNG Salva come JPEG
Categoria #
all - tutte 52.057
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 52.057
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022737 0 0 0 43 33 20 16 264 19 44 110 188
2022/20231.620 134 273 28 131 133 184 2 76 571 4 60 24
2023/2024737 43 70 29 31 15 18 211 23 80 16 87 114
2024/20252.294 55 203 165 106 297 109 203 208 358 122 340 128
2025/20264.248 267 220 181 537 548 413 739 233 457 335 235 83
2026/20271.044 211 148 257 428 0 0 0 0 0 0 0 0
Totale 12.754